Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!
### The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!
Patient Story
#CART #PatientStory #lymphoma #TP53 #DLBCL #CARTTherapy
Meet Mrs. Qin, a true fighter and the first brave patient in China to receive Fosun Kite’s Axicabtagene Ciloleucel in a CAR-T clinical trial. Her story is one of hope, perseverance, and the power of innovation.
In early 2017, a routine check-up uncovered a small lump in her neck, leading to a diagnosis of diffuse large B-cell lymphoma (DLBCL) with a TP53 gene mutation—a high-risk condition. After enduring 12 rounds of grueling chemotherapy, the cancer still returned. Just when hope seemed to be fading, Mrs. Qin became the first patient in China to join a groundbreaking CAR-T therapy trial at Ruijin Hospital under the care of Dr. Zhao Weili. She was a pioneer, much like Emily Whitehead in the U.S., the world’s first pediatric patient to receive CAR-T therapy.
Mrs. Qin recalls the challenging days of her treatment, which involved high fevers and fatigue, yet the unwavering support of Dr. Zhao’s team helped her push through. The cutting-edge CAR-T treatment not only controlled the tumor but led her into complete remission. Six years later, she remains cancer-free and now serves as a volunteer at the hospital, inspiring others who are fighting the same battle.
During the first “CAR-T Therapy Survivor Conference” in Wuhan of China, Mrs. Qin took the stage to share her emotional journey. Her story moved everyone in attendance, from fellow patients to medical experts, as she expressed gratitude for the love and care she received. “Ruijin Hospital is not just where I found a new lease on life, but a home filled with compassion and world-class medical expertise,” she shared.
Mrs. Qin’s tale of courage is a beacon of hope for those still battling the disease. Her message is simple: “No matter how tough the road, never lose faith. After every storm, the rainbow will appear.”
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#ChinaCAR-T #CAR-TTherapy #CancerSurvivor #MedicalBreakthrough #FosunKite #DLBCL #CancerRemission #InnovativeMedicine #HopeHealing #RuijinHospital #ChineseMedicalPioneers #PatientStories #EmilyofChina
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**
**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**
Lupus
#LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus #patientstory #SLE
In June 2024, 13-year-old Qingqing experienced a major turning point in her life. A year after being diagnosed with systemic lupus erythematosus (SLE), she received innovative CAR-T therapy at Shanghai Children’s Medical Center and successfully achieved disease remission. SLE, often referred to as the “incurable cancer,” is an autoimmune disease that affects millions of people worldwide, severely damaging the brain, lungs, kidneys, and blood system. Even when not in an acute flare, patients often suffer from chronic symptoms such as fatigue, rashes, pain, and fever.
Qingqing’s treatment marks a significant breakthrough in the global fight against SLE. Previously, SLE patients could only rely on lifelong medications, such as steroids and immunosuppressants, to control the disease and prevent severe complications. However, these drugs often come with side effects and long-term organ damage. Qingqing’s case has offered the world new hope. A team led by Dr. Li Benshang, chief physician of the Hematology and Oncology Department, and Dr. Yin Lei, head of the Nephrology Department, pioneered the use of CAR-T therapy in SLE treatment and initiated a clinical study. After just two months of treatment, Qingqing’s condition has fully gone into remission, and all medications were discontinued.
CAR-T therapy was originally used in cancer treatment by extracting a patient’s T cells and genetically modifying them to recognize and kill abnormal cells in the body. In the treatment of SLE, CAR-T therapy eliminates the abnormal plasma cells producing autoantibodies, effectively “resetting” the patient’s immune system and addressing the root cause of the disease.
Qingqing’s success story is not only a milestone in China’s CAR-T technology but also a major leap forward in the global treatment of autoimmune diseases like SLE. Since the first CAR-T treatment cured an SLE patient in 2021, numerous clinical trials have been conducted worldwide, and several Chinese hospitals have also achieved success. However, while early results are encouraging, further research and validation are needed to confirm the long-term safety and efficacy of the treatment.
With 20% of the global population affected by various types of autoimmune diseases, CAR-T therapy holds the potential to bring new life to millions of patients. China’s ongoing research and international collaboration in this field offer unprecedented hope for overcoming persistent diseases like SLE.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
(Https://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com
#CAR-Ttherapy #LupusTreatment #AutoimmuneDisease #MedicalInnovation #ChinaHealthcare #Immunotherapy #CancerTreatment #HealthBreakthrough #HopeForLupus #FutureOfMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Seeking Medical Treatment Abroad: The Best CAR-T Therapy is in China! The First Russian Multiple Myeloma Patient Successfully Achieves Complete Tumor Clearance and CR!
**Seeking Medical Treatment Abroad: The Best CAR-T Therapy is in China! The First Russian Multiple Myeloma Patient Successfully Achieves Complete Tumor Clearance and CR!**
patient story
Over the five years following his diagnosis of high-risk multiple myeloma, Mr. F endured relentless pain. Despite undergoing various chemotherapy regimens and two transplants, he could never completely escape the nightmare of unpredictable tumor recurrence and progression. Fortunately, by the end of 2023, his condition temporarily stabilized. Accompanied by top hematology experts from Russia, Mr. F traveled to China to receive CAR-T therapy, achieving optimal results with complete tumor eradication and CR (complete remission).
Achieved CR! In February 2024, Mr. F and his family successfully returned to Russia to resume their happy lives.
(Note: To protect patient privacy, pseudonyms are used in the text, and the medical details and treatment process have been slightly modified.)
**Common Back Pain Turned Out to Be High-Risk Multiple Myeloma**
Mr. F, 63, is the vice principal of a technical college in St. Petersburg, Russia. He has a successful career and a happy family with his wife, one son, and two daughters. In the months leading up to Christmas 2017, Mr. F experienced worsening back pain, with severe pain in the lumbar region. Accompanied by his family, he went to the hospital for a thorough examination. The final diagnosis was multiple myeloma, with osteolytic lesions in more than three areas. The doctor informed Mr. F that, based on the comprehensive assessment of various test results, his myeloma was classified as high-risk (IgG-type, DS-Stage IIIA, ISS-Stage II), making it difficult to treat, prone to relapse, and with a poor prognosis. This devastating news struck suddenly, plunging the entire family into shock and panic. In an interview, Mr. F said, “In Chinese culture, Confucius said, ‘When Heaven is about to place a great responsibility on a man, it always first frustrates his spirit,’ viewing it as a life test. In Western culture, it is seen as God’s punishment, a trial one must endure, with the outcome entirely dependent on how one faces these challenges. I must choose to fight!”
**Relapse and Progression: The Unshakeable Nightmare for Multiple Myeloma Patients**
After two days of shock and panic, Mr. F decided to pull himself together and seek the best treatment to fight the tumor. Mr. F and his family consulted many doctors and clinics in Spain, Munich, and Heidelberg. Upon learning that CAR-T therapy had remarkable curative effects on hematologic malignancies, they felt a glimmer of hope, which was soon extinguished. At that time, very few countries offered CAR-T therapy, mostly in developed nations, and the exorbitant cost of nearly a million dollars made it unaffordable even for the well-off Mr. F. To control the disease as quickly as possible, Mr. F underwent traditional CVD therapy in Russia at the beginning of 2018, followed by his first autologous bone marrow transplant, achieving partial remission (PR). Unfortunately, just ten months later, his multiple myeloma relapsed. After switching to a second-line chemotherapy regimen, he underwent a second autologous bone marrow transplant. Despite receiving the most aggressive treatment and enduring life-threatening side effects, tumor lesions persisted in his body, like a ticking time bomb that could explode at any moment. Although maintenance therapy temporarily stabilized the disease, Mr. F and his family remained vigilant. They knew that high-risk myeloma was likely to relapse and progress again in the short term. If the disease worsened once more, they would face a desperate situation with no available treatments.
**Global Comparison Shows the Best CAR-T Therapy is in China!**
To completely rid himself of cancer and escape the nightmare of constant relapse and deterioration, five years later, Mr. F and his family once again sought the possibility of a cure through CAR-T therapy worldwide. They conducted extensive research on the CAR-T therapies already on the market and consulted numerous hospitals and experts in Europe, including in India and Israel. To his surprise, despite five years passing, there had been no significant progress in these countries. Almost every expert mentioned that Chinese hospitals had made tremendous advancements in the CAR-T field, surpassing even those in Europe and the United States. Especially for multiple myeloma, on June 30, 2023, China introduced the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and his attending physician immediately contacted Shanghai Jiahui International Hospital in China for an initial remote consultation. Jiahui Hospital, an internationally aligned oncology center with a professional multidisciplinary MDT team, conducted a preliminary evaluation. They concluded that the Iquilence (BCMA CAR-T) treatment plan would be most beneficial and developed a comprehensive plan, addressing all questions and concerns of Mr. F and the Russian experts, ultimately reaching a consensus on the treatment plan.
Professor Li Hua, Director of Oncology at Jiahui International Cancer Center, and his team of Russian hematology experts discussed Mr. F’s treatment plan. Although Mr. F was somewhat aware of China’s medical advancements, he couldn’t imagine that China’s healthcare had surpassed that of the developed Western countries. Therefore, in November 2023, Mr. F’s attending physician, a renowned Russian hematology expert, accompanied him to China to evaluate the feasibility of Chinese CAR-T therapy on-site. Their first stop upon arriving in China was to meet with Jiahui Hospital’s international multidisciplinary treatment team and tour the medical environment that adheres to international nursing standards.
Professor Li Hua, Director of Jiahui International Cancer Center, and his team provided a detailed introduction to the CAR-T treatment plan. Compared to traditional treatments, CAR-T has unique advantages. Firstly, it is a highly personalized treatment that adjusts the patient’s immune system through genetic engineering, providing a more precise response to cancer treatment. Secondly, CAR-T shows significantly higher efficacy in complex cases, which traditional treatments cannot achieve. Iquilence has an overall response rate of nearly 99% and a complete response rate of up to 82.4%. More importantly, fully human CAR-T not only maintains the patient’s quality of life but also provides more durable treatment effects. Additionally, a one-time infusion treatment achieves rapid and effective results, reducing the pain and burden during the treatment process and bringing hope for a cure.+
The second stop for Mr. F and the Russian experts was a visit to the production facility of the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and the Russian experts were impressed to learn that this exceptional therapy was not only entirely developed in-house, but the lentiviral vector was also independently developed. The facility boasts a complete end-to-end development platform and a self-built manufacturing base.
Finally, Mr. F overcame all his concerns and was convinced that China’s fully human BCMA CAR-T solution was world-leading. He decided to undergo treatment in China.
All Tumors Cleared for the First Time, Advanced Myeloma Achieves CR!
In December 2023, just before another Christmas five years after his diagnosis, Mr. F and his family arrived in China, full of hope for a cure, to officially begin his CAR-T journey. At Shanghai Jiahui International Hospital, Mr. F underwent thorough examinations, and after meeting all the requirements, he successfully underwent apheresis, the process of collecting T cells. These cells were then transported back to the factory within 24 hours to create a precisely targeted anti-cancer weapon tailored for Mr. F.
On January 20, 2024, he received lymphodepleting chemotherapy with fludarabine and cyclophosphamide.
On January 25, 2024, the CAR-T cells, carrying the hopes of Mr. F’s entire family, were transported to him by the pharmacy team using professional cold chain logistics. After multiple inspections, unpacking, and reactivation, a small bag of milky white liquid was infused back into Mr. F. The doctors explained that this liquid contained hundreds of billions of “special forces” T cells, which, once in the body, would begin an intense sweep to eradicate the myeloma cells completely.
The infusion process went smoothly. What deeply moved Mr. F and his family was that whenever he felt anxious, the medical team would hold his hand, giving him confidence and strength.
Although a mild cytokine release syndrome (CRS), which is common after CAR-T therapy, occurred post-infusion, the medical team at Jiahui Hospital was very experienced in handling this. With symptomatic treatment, the symptoms improved in about a week. On the 14th day after the infusion, the evaluation showed that the CAR-T cells had expanded effectively in Mr. F’s body, reaching 10^9.
Mr. F said that, unlike the two painful transplant experiences, despite knowing that CAR-T therapy has side effects, the medical team clearly informed him about the reactions he might have at different stages and assured him that the medical staff would address them immediately. As a result, he felt no concerns or fears.
Before the Chinese New Year in 2024, Mr. F was discharged and returned to Russia for further follow-up in his home country. Professor Li Hua said, “The treatment results met our expectations, with significant improvements in key indicators such as serum M protein, free light chains, and disease symptoms. All functional statuses have improved.”
In May 2024, the PET-CT results showed that Mr. F’s lesions had disappeared, and he finally achieved complete remission (CR). This means that after battling multiple myeloma for six years, he has finally won!
A Brighter Future: China Will Become the Best Treatment Destination for Advanced Myeloma Patients!
Now, Mr. F not only resumes his happy and fulfilling life, but he and his wife have also returned to their beloved careers. He currently serves as the General Manager of the UNESCO Mineral Resources Education Center.
Mr. F said, “When I came to China and saw the medical conditions and experienced the best care firsthand, I felt a deep sense of pride for China. It is regrettable that Russia is currently unable to achieve this level of care. However, I will bring my experiences here back to Russia and share them. China’s medical system is world-leading, and choosing to come to China was the right decision!”
In an interview, Mr. F’s wife said, “Although we are past retirement age, we both have very important careers. This CAR-T treatment in China has given us a very precious experience. We have more time to listen to each other’s thoughts, support each other, and get through difficult times together.”
Professor Li Hua, Director of the International Oncology Hospital and Director of the Department of Oncology, said in an interview:
“Clinical research on CAR-T therapy started relatively early in China. Especially since 2020, the number of CAR-T clinical trials in China has far surpassed that in the United States, giving us extensive experience from laboratory research to clinical application.
Moreover, CAR-T treatment in China is more cost-effective, providing patients with a more competitive option.
Most importantly, China has sufficient commercial-quality production capacity. Patients can receive treatment quickly without waiting, which is crucial for those with malignant hematologic diseases who need timely treatment.”
Professor Li Hua, Director of Oncology at Jiahui International Hospital,
The emergence of CAR-T cell therapy has brought new hope to cancer patients worldwide. China’s CAR-T therapy offers outstanding efficacy, good safety, low cost, and rapid preparation advantages. Several international hospitals have opened green channels for overseas patients, making China the best treatment destination for global late-stage multiple myeloma patients!
References:
[1] Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.[2] 2023 IMS. P-290.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient
In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless.
Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.
In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M. What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!
Reference：
[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.
[2] 2023 IMS. P-290.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Light of Hope – The Starting Point for Multiple Myeloma Patients
### Light of Hope – The Starting Point for Multiple Myeloma Patients
Ms. Teresa sat in the comfortable seat of the apheresis room, watching the nurse gently insert the needle into her arm to draw the precious white blood cell samples. These white blood cells would become the core material for CAR-T therapy, engineered and then reintroduced into her body to become a powerful force against cancer.
In the operating room, machines hummed softly, precisely separating the T cells from Teresa’s body. These cells, which had faithfully performed their duty of protecting her body, would now be re-educated to become a precise strike team against cancer cells. Teresa closed her eyes and silently prayed that this apheresis would infuse her body with the strength to drive the disease out of her life.
The apheresis process lasted several hours, with medical staff carefully monitoring each step to ensure enough high-quality cells were collected. The extraction of these cells was not only a technical challenge but also a stringent test of the medical team’s professional capabilities.
After the apheresis was completed, Teresa felt somewhat relieved. She knew this was just the first step in a long treatment journey, but it was also an important starting point filled with hope. In the apheresis room, she felt the warmth and professionalism of the medical team, which filled her with confidence and hope for the future treatment.
Back in her ward, Teresa gently closed her eyes as she lay on the bed. She pondered how the coming days would unfold, hoping that this apheresis would bring her the strength to overcome the disease and regain her health.
Apheresis, as the first step of the treatment journey, marked a new chapter in Teresa’s brave fight against cancer and ignited a flame of hope for her future recovery.
#ThePathOfHope #FightingCancer #JourneyOfCARTTherapy #TogetherWithTongji #FullyHumanCART #HopeWithFUCASO #EquecelApproval #HealthReborn #UnitedInPrayer #MultipleMyeloma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient
### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University
CAR-T Therapy
On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough in the field of leukemia cellular immunotherapy in China. Recently, The First Affiliated Hospital of Chongqing Medical University successfully treated a young patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL), demonstrating the remarkable efficacy of this innovative therapy.
**Successful Case**
The patient, a 20-year-old female, was diagnosed with Ph+ B-ALL in early 2021. Despite undergoing tyrosine kinase inhibitors (TKI) combined with chemotherapy and hematopoietic stem cell transplantation (HSCT), her disease relapsed multiple times. Finally, she tried CAR-T therapy. On February 23, 2024, the patient received a transfusion of Inaticabtagene Autoleucel Injection. Just one month after the transfusion, she achieved complete remission (CR) and minimal residual disease (MRD) negativity. Currently, the patient is recovering well and is about to return to school.
**Professional Care from the Medical Team**
Throughout the treatment, the expert team at The First Affiliated Hospital of Chongqing Medical University demonstrated exceptional medical skills and meticulous care. Professor Li noted that after multiple treatment failures, the patient chose the innovative therapy of Inaticabtagene Autoleucel Injection, which ultimately yielded gratifying results. During the CAR-T transfusion, the medical team closely monitored the patient’s condition, ensuring the safety and effectiveness of the treatment. The patient’s positive attitude and family support also laid the foundation for successful treatment.
**Support from Commercial Insurance**
This treatment not only relied on advanced medical technology but also benefited from the support of the patient’s family’s commercial insurance. During the treatment, the patient’s family actively applied for commercial insurance claims and successfully obtained full compensation, significantly reducing the financial burden. The support from commercial insurance increased the accessibility of the treatment, providing solid backing for the patient’s recovery.
**Future Prospects**
The approval of Inaticabtagene Autoleucel Injection has brought new hope to B-ALL patients, especially young ones. The excellent efficacy and safety of CAR-T therapy will significantly improve their quality of life. With more successful cases emerging, CAR-T therapy is expected to become the new standard for B-ALL treatment.
The successful case at The First Affiliated Hospital of Chongqing Medical University not only showcases the immense potential of Inaticabtagene Autoleucel Injection in treating leukemia but also provides valuable experience and reference for future clinical applications. The patient’s recovery journey is inspiring, symbolizing not only physical recovery but also a rebirth of the spirit.
**Conclusion**
The successful application of CAR-T therapy has shown leukemia patients a light of recovery. The professional team at The First Affiliated Hospital of Chongqing Medical University will continue to promote this innovative therapy, bringing hope and new life to more patients. With the advancement of medical technology and the support of commercial insurance, the future of patients will be even brighter.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CARTherapy #LeukemiaTreatment #InnovativeMedicine #ChongqingMedicalUniversity #MedicalBreakthrough #NewLife #CommercialInsurance #PatientRecovery #CancerTreatment #MedicalTechnology #PatientStory #MedicalAdvancement #HopeAndHealing #ChineseHealthcare #CARTTreatment #PhALL #HealthyFuture
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient
Patient story
Subtitle: Fighting for Love! A story of miraculous rebirth after all treatment options failed for a late-stage multiple myeloma patient in Thailand, who underwent CAR-T therapy in China.
Preface: When all treatment options had been exhausted, cancer progressed rapidly, and doctors regretfully said that Ms. M had no response to any medication. This situation could only lead to palliative care, meaning Ms. M had no chance to fight this disease anymore; her life was now on borrowed time. Fortunately, Ms. M’s family found new hope in China – CAR-T therapy. With the companionship of her family, Ms. M came to China and underwent the world’s first fully human BCMA CAR-T therapy. In just 22 days after treatment, all tumors miraculously disappeared, achieving complete remission (CR), and Ms. M was given a new lease on life!
In June 2021, the life of 58-year-old Ms. M experienced persistent back pain for over months. After detailed examinations at the hospital,resulting in a diagnosis of multiple myeloma. To quickly control the condition, Ms. M received treatments including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation.
In June 2023, the disease relapsed and Ms. M did not respond to any of these treatments. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless, indicating that Ms. M’s life was now on borrowed time! Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.
In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M.
On September 8, 2023, Ms. M finally officially entered the CAR-T treatment process. After all examination items met the requirements, single-cell collection was performed first.
Bridge therapy began on September 11, 2023;
Local radiotherapy to relieve bone pain started on September 24, 2023;
Fludarabine plus cyclophosphamide chemotherapy was administered from October 9-12, 2023;
Finally, on October 14, a small bag of milky-white liquid was infused into Ms. M’s body. The doctor said that inside were billions of “special” T cells that could precisely kill multiple myeloma cells. Once inside the body, they would initiate a mode of frenzied sweeping, wiping out cancer cells completely.
What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!
Every day now is precious to Ms. M. She can go shopping, chat with her family, enjoy delicious food with her family, and travel around the world with them, returning to the happy times before she fell ill. The only difference is that Ms. M and her family visit a fixed destination every month now – Shanghai, China. They have become accustomed to hearing the sacred announcement from the doctors here: no cancer in her body, continuing remission.
This is a microcosm of countless cancer patients overcoming the disease. The emergence of CAR-T cell therapy has brought new hope to cancer patients. I believe that in the future, more patients will be able to regain a new life like Ms. M.
Reference：
[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.
[2] 2023 IMS. P-290.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China
Hope of patient
“When I first arrived, I couldn’t walk and had a lot of pain in my chest and back. Now, I don’t have these symptoms anymore, and I can walk for more than ten minutes every day.”
Meet Julian, a patient from Pakistan who faced the daunting challenge of a relapse in his battle against Multiple Myeloma. Despite undergoing various treatments, relief seemed elusive.
Julian’s wife stumbled upon groundbreaking research published by Xuzhou Medical University, highlighting innovative cell therapy for Multiple Myeloma developed by the Tumor Biotherapy Research Institute and affiliated hospitals.
Seeking further treatment, Julian and his wife embarked on a journey to Xuzhou Medical University Affiliated Hospital. Upon arrival, thorough examinations were conducted to assess his condition and formulate a tailored treatment plan.
Julian underwent T-cell collection at the Hematology Department’s Cell Collection Room, with the harvested cells processed into CAR-T cells by Xuzhou Medical University’s Cancer Research Institute. Two weeks later, he received an infusion of immune cells (CD19CAR-T cells, BCMACAR-T cells).
A month later, bone marrow cytology revealed complete remission of the primary disease. His attending physician continued medical observations, confirming positive treatment outcomes through comprehensive examinations.
“Previously, I couldn’t sit like this, and walking was very difficult. It was also very uncomfortable to lie down.”
”After receiving CAR-T treatment, you can see that I can now sit normally, walk normally, and my mobility is gradually increasing.
My improvement is very significant.”
From treatment initiation to Julian’s discharge and return home, the entire process took just one and a half months.
Julian’s journey stands as a beacon of hope, showcasing the transformative potential of innovative medical interventions in the fight against Multiple Myeloma.
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Expert Perspective: Options for CAR-T Therapy in Thai Patients
🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈
🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.
🌼We will continue to follow up on the patient’s treatment progress and provide further updates.
#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory